Hematology: Nilotinib and dasatinibg - New 'magic bullets' for CML?

Nature Reviews Clinical Oncology

Volumn 7, Issue 10, 2010, Pages 557-558

  Breccia, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ABNORMAL LABORATORY RESULT; BLOOD TOXICITY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; DRUG ANTAGONISM; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; TREATMENT OUTCOME;

EID: 77957596333     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.151     Document Type: Short Survey

References (10)

1. Deininger, M. et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood 114, a1126 (2009).
2. Marin, D. et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112, 4437-4444 (2008).
3. Cortes, J. E. et al. Phase III, randomized, openlabel study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28, 424-430 (2010).
4. Shah, N. P. et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinibresistant and intolerant chronic phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212 (2008).
5. Kantarjian, H. M. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546 (2007).
6. + chronic myeloid leukaemia. Blood 114, 4933-4938 (2009).
7. Cortes, J. E. et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukaemia. J. Clin. Oncol. 28, 398-404 (2010).
8. Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N. Engl. J. Med. 362, 2251-2259 (2010).
9. Kantarjian, H. M. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia. N. Engl. J. Med. 362, 2260-2270 (2010).
10. Baccarani, M. et al. Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27, 6041-6051 (2009).